← boardnext 2026-08-20next 2030-01-17
TAK
Takedadistress 0/10 · well-funded / low risk$16.76-1%today-11% from 52w high
Lead: Hemophilia B · est. market ~$13B (approx, global)
Revenue
$4505720M
Liquidity
$1085679M
Runway
—
Shares 1y
0%
Price & events
+5.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
+0.2%
1W
+5.8%
1M
+0.7%
3M
+2.9%
6M
+13.7%
1Y
+28.4%
2Y
+6.2%
5Y
-0.5%
All
Overview
- Market Cap
- $26.11B
- Enterprise Value
- $3.80T
- Volume
- 224.51K
- 52 Week Range
- $13.23 – $18.80
- Total Shares
- 1.56B
- Float Shares
- 3.16B
- Short %
- 0.17%
- % Held by Insiders
- 0.07%
- % Held by Institutions
- 3.11%
- RVOL
- 0.07x
- Beta
- 0.09
Pipeline stages · 2 programs
TAK-360
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AskBio009
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
Catalyst news & presentations · 1
- 2026-07-30Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,557,765,596 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+25% upside) · 3 analysts
- no recent rating changes
Recent news
- 2026-07-22Takeda Pharmaceutical Co Ltd (0RN3) Q4 2023 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-20Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India - Reuters
- 2026-07-19TAK Stock Price and Chart — NYSE:TAK - TradingView
- 2026-07-19TAK Stock Price and Chart — NYSE:TAK - TradingView
- 2026-07-18Bernstein Maintains TAKEDA PHARMACEUTICAL CO LTD(TKPHF.US) With Buy Rating, Cuts Target Price to $42.47 - 富途牛牛
- 2026-07-17Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials - Benzinga
- 2026-07-13Takeda Pharmaceutical (TAK) holder to sell 4,319 ADSs from RSU awards - Stock Titan
- 2026-07-13Takeda (TAK) holder to sell 33,454 ADSs valued at about $560K - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.